Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 plus Lenalidomide in Relapsed/Refractory B-Cell NHL
NCT03645395Phase 2Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of MT-3724 in B-cell non-Hodgkin lymphoma (5 arms), sponsored by Molecular Templates, Inc. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting Toxicity up to 1 year, Number of Participants With Abnormal Laboratory Parameters up to 1 year and 1 more. Started Apr 2019; status: terminated.
02
Drugs
MT-3724
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03645395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645395.